RSV Vaccination Efforts Intensify with Increased Supply and Public Pressure

The Biden administration has secured a deal with drug manufacturers to make an additional 230,000 doses of the respiratory syncytial virus (RSV) shot available for infants by January, addressing a widespread shortage that has caused frustration among parents and pediatricians. The administration has been pressuring manufacturers to ramp up supply, with top officials engaging in high-level meetings to ensure that the shortfall doesn't become severe. The shortage has raised concerns about the availability of RSV shots as the RSV season peaks. The administration's efforts to boost supply come as the rollout of RSV shots serves as a test for post-Covid public health initiatives.